EADV 2025: Interim Real-World Data from ADlife on Lebrikizumab in Moderate-to-Severe AD
New interim real-world data from the ADlife study explore the effectiveness and safety of lebrikizumab in adults with moderate-to-severe atopic dermatitis. Early results at weeks 4 and 16 suggest promising clinical outcomes in a comorbid, treatment-experienced population.
Image courtesy of the European Academy of Dermatology and Venereology (EADV).
Få tillgång
Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.
- Få tillgång
- Om du redan har en profil: Logga in
